Pinto-Cardoso Sandra M, Aguilar-Vargas Adriana, López-Filloy Mariana, Chávez-Torres Monserrat, Murakami-Osawara Akio, Briceño Olivia, Romero-Mora Karla, Rodríguez-Moguel Nadia, Salgado Montes de Oca Gonzalo, Ávila-Ríos Santiago
Departamento del Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Ciudad de México, México.
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México.
BMC Microbiol. 2025 Sep 1;25(1):569. doi: 10.1186/s12866-025-04313-9.
Unwanted weight gain is often reported in people living with HIV (PWH) who start on or switch to integrase strand transfer inhibitors (INSTI). Mechanisms are incompletely understood. An unintended off-target of INSTI might be the gut microbiota.
We explored the fecal microbiota of treated aviremic PWH (n = 70) who switched from efavirenz (EFV)- to a bictegravir (BIC)-based regimen. 16S rRNA sequencing, and enzyme-linked immunosorbent assays were used to characterize the fecal microbiota and quantify markers of HIV disease progression. A cohort of high-risk HIV-negative individuals (n = 18) was included to address differential effects of antiretroviral therapy (ART) on the fecal microbiota.
This real-life cohort was predominantly male (n = 63) and mostly men who have sex with men (n = 40). All PWH were on the same antiretroviral regimen for at least 1 year; the mean time on ART was 10.83 ± 5.530 years and all had undetectable plasma viral loads (< 40 HIV-1 RNA copies/mL). PWH gained a median weight of 3.375 kg and the mean percent weight change relative to baseline was 4.32%. Seven (10%) PWH gained significant weight (> 10% relative to baseline). Switching to a BIC-based regimen had contrasting effects. PWH on BIC/FTC/TAF showed decreased microbial translocation (soluble CD14, sCD14), decreased enterocyte damage (intestinal fatty-acid binding protein, I-FABP), and increased alpha diversity (richness and shannon); all indicative of a better restoration of the gut mucosa and microbiota. Conversely, increases in sCD163, monocyte chemoattractant protein 1 (MCP-1) and decreases in adiponectin, markers linked to cardiovascular disease, insulin resistance and adiposity, were unfavorable.
Our data suggest that INSTI have a less detrimental effect on the gut microbiota compared to EFV-based regimen. The link between weight gain on INSTI and the gut microbiota was not readily apparent.
开始使用或换用整合酶链转移抑制剂(INSTI)的人类免疫缺陷病毒感染者(PWH)常出现体重增加。其机制尚未完全明确。INSTI的一个意外脱靶效应可能是肠道微生物群。
我们研究了70例从依非韦伦(EFV)转换为基于比克替拉韦(BIC)方案治疗的病毒血症已缓解的PWH的粪便微生物群。采用16S rRNA测序和酶联免疫吸附试验来表征粪便微生物群并量化HIV疾病进展标志物。纳入一组高危HIV阴性个体(n = 18)以研究抗逆转录病毒疗法(ART)对粪便微生物群的不同影响。
这个真实队列主要为男性(n = 63),且大多是男男性行为者(n = 40)。所有PWH都接受相同的抗逆转录病毒方案至少1年;ART的平均时间为10.83±5.530年,且所有人血浆病毒载量均不可检测(<40个HIV-1 RNA拷贝/mL)。PWH体重中位数增加3.375 kg,相对于基线的平均体重变化百分比为4.32%。7例(10%)PWH体重显著增加(相对于基线增加>10%)。换用基于BIC的方案有不同的影响。接受BIC/FTC/TAF治疗的PWH微生物易位(可溶性CD14,sCD14)减少,肠细胞损伤(肠脂肪酸结合蛋白,I-FABP)减少,α多样性(丰富度和香农指数)增加;所有这些都表明肠道黏膜和微生物群的恢复更好。相反,与心血管疾病、胰岛素抵抗和肥胖相关的标志物可溶性CD163、单核细胞趋化蛋白1(MCP-1)增加以及脂联素减少则是不利的。
我们的数据表明,与基于EFV的方案相比,INSTI对肠道微生物群的有害影响较小。INSTI导致体重增加与肠道微生物群之间的联系并不明显。